New Government Report: New Jersey Syringe Access Program Demonstration Project Interim Report: Implementation of P.L. 23006, c.99, Blood-borne Disease Harm Reduction Act

New Jersey Syringe Access Program Demonstration Project Interim Report: Implementation of P.L. 23006, c.99, Blood-borne Disease Harm Reduction Act
by Laurence E. Ganges
Paperback, 17 pages, 2010, ISBN: 9781437935059, $15.00

Four years ago, New Jersey became the last state to approve needle-exchange programs to curb the spread of HIV/AIDS by drug addicts, reports the Philadelphia Inquirer. A new state Health Department report shows those efforts are making a difference, and offers evidence that the pilot programs should continue. But they are threatened by a lack of funding.

Injection drug use is one of the most common methods of transmission for a number of preventable life‐threatening diseases, including HIV and Hepatitis C.

Along with drug treatment and behavioral health interventions, syringe access programs are an important component in attempting to prevent/reduce the risks associated with injection drug use.

On Dec. 19, 2006, Governor Corzine signed the “Blood‐borne Disease Harm Reduction Act,” which allows a maximum of six municipalities in NJ to establish a demonstration syringe access program.

This report presents an evaluation of the Demonstration Project based on data collected from the inception of the first site from Nov. 27, 2007 through Dec. 31, 2009. Charts and tables.

Purchase this print-on-demand publication for $15.00:

Advertisements